Surveillance of drug resistance tuberculosis based on reference laboratory data in Ethiopia

被引:15
|
作者
Diriba, Getu [1 ]
Kebede, Abebaw [1 ]
Tola, Habteyes Hailu [1 ]
Alemu, Ayinalem [1 ]
Tadesse, Mengistu [1 ]
Tesfaye, Epherem [1 ]
Mehamed, Zemedu [1 ]
Meaza, Abiyot [1 ]
Yenew, Bazezew [1 ]
Molalign, Hilina [1 ]
Dagne, Biniyam [1 ]
Sinshaw, Waganeh [1 ]
Amare, Misikir [1 ]
Moga, Shewki [1 ]
Abebaw, Yeshiwork [1 ]
Sied, Getachew [1 ]
机构
[1] Ethiopian Publ Hlth Inst, Addis Ababa, Ethiopia
关键词
Tuberculosis; Multidrug-resistant tuberculosis; Rifampicin resistance; Isoniazid resistance; MULTIDRUG-RESISTANT; PREVALENCE; 1ST;
D O I
10.1186/s40249-019-0554-4
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
BackgroundBoth passive and active surveillance of drug resistance have an important role in tuberculosis (TB) control program. Surveillance data are important to estimate the magnitude of drug resistance TB, to know the trend of the disease, assess the performance of the program, and to forecast diagnosis and treatment supplies. Therefore, this study aimed to determine the prevalence and the proportion of drug resistant tuberculosis in Ethiopia based on passively collected data.MethodsA cross-sectional study was conducted at the National Tuberculosis Reference Laboratory and seven Regional TB laboratories in Ethiopia on a retrospective data collected from July 2017 to June, 2018. Data were collected by standardized checklist from TB culture laboratory registration book. Percentage of recovery rate, contamination rate, and prevalence of drug resistance TB were determined by Statistical Package for Social Science (SPSS) version 23.ResultOf 10134TB suspected individuals included into this analysis, 1183 (11.7%) were culture positive. The overall contamination proportion was 5.3% and nontuberculous mycobacteria proportion was 0.98%. First-line drug susceptibility test was performed for 329 Mycobacterium tuberculosis complex isolates, and the proportion of resistance was 5.7 and 6.3% for isoniazid and rifampicin respectively. The proportion of multidrug-resistant tuberculosis (MDR-TB) was 4.3% in new patients, while 6.7% in previously treated patients. However, there was no category for 0.6% patients, and the overall proportion of MDR-TB was 11.6%.ConclusionsThe result of this study indicated that MDR-TB is a serious public health problem in Ethiopia. Thus, strengthen prevention and control program is vital to halt the burden of drug resistant TB in the country.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] TUBERCULOSIS IN AUSTRALIA: BACTERIOLOGICALLY CONFIRMED CASES AND DRUG RESISTANCE, 2007 A report of the Australian Mycobacterium Reference Laboratory Network
    Lumb, Richard
    Bastian, Ivan
    Carter, Robyn
    Jelfs, Peter
    Keehner, Terillee
    Sievers, Aina
    COMMUNICABLE DISEASES INTELLIGENCE, 2009, 33 (03) : 298 - 303
  • [22] TUBERCULOSIS IN AUSTRALIA: BACTERIOLOGICALLY CONFIRMED CASES AND DRUG RESISTANCE, 2006 A REPORT OF THE AUSTRALIAN MYCOBACTERIUM REFERENCE LABORATORY NETWORK
    Lumb, Richard
    Bastian, Ivan
    Gilpin, Chris
    Jelfs, Peter
    Keehner, Terillee
    Sievers, Aina
    COMMUNICABLE DISEASES INTELLIGENCE, 2008, 32 (01) : 12 - 17
  • [23] Epidemiological profile of patients with rifampicin-resistant tuberculosis: an analysis of the Uganda National Tuberculosis Reference Laboratory Surveillance Data, 2014-2018
    Bahizi, Gloria
    Majwala, Robert Kaos
    Kisaka, Stevens
    Nyombi, Abdunoor
    Musisi, Kenneth
    Kwesiga, Benon
    Bulage, Lilian
    Ario, Alex Riolexus
    Turyahabwe, Stavia
    ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL, 2021, 10 (01)
  • [24] Drug-resistant Tuberculosis: First Line Drug Resistance Pattern among Mycobacterium tuberculosis Strains Isolated from a Reference Laboratory in Kerala State, India
    Murthy, Neetha S.
    Nair, Sanjeev
    Ramya, P. K.
    George, Renu Susan
    Ravikrishnan, B.
    Kumar, M. Sunil
    Philip, Sairu
    Rakesh, P. S.
    Balakrishnan, Shibu
    JOURNAL OF PURE AND APPLIED MICROBIOLOGY, 2021, 15 (04): : 1882 - 1891
  • [25] Surveillance of Rifampicin Resistance With GeneXpert MTB/RIF in the National Reference Laboratory for Tuberculosis at the Institut Pasteur in Bangui, 2015-2017
    Farra, Alain
    Manirakiza, Alexandre
    Yambiyo, Brice Martial
    Zandanga, Germain
    Lokoti, Boris
    Berlioz-Arthaud, Alain
    Ngaya, Gilles
    Hermana, Georges
    Ourandji, Louis Medard
    Ignaleamoko, Albert
    Komangoya-Nzonzo, Aristide Desire
    Simelo, Jean Pierre
    Iragena, Jean de Dieu
    OPEN FORUM INFECTIOUS DISEASES, 2019, 6 (03):
  • [26] Integration of HIV testing in tuberculosis drug resistance surveillance in Kazakhstan and Kenya
    Klinkenberg, E.
    van den Hof, S.
    Tursynbayeva, A.
    Kipruto, H.
    Wahogo, J.
    Pak, S.
    Kutwa, A.
    L'Herminez, R.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2012, 16 (05) : 615 - 617
  • [27] Does Current Drug Resistance Surveillance Provide Useful Information in Tuberculosis?
    Leung, Chi Chiu
    Yew, Wing Wai
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179 (01) : 82 - 82
  • [28] Surveillance of Mycobacterium tuberculosis drug resistance France, 1995-1997
    Robert, J
    Trystram, D
    Truffot-Pernot, C
    Carbonnelle, B
    Grosset, J
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2000, 4 (07) : 665 - 672
  • [29] Next steps in the global surveillance for anti-tuberculosis drug resistance
    Pablos-Mendez, A
    FIREPOWER IN THE LAB: AUTOMATION IN THE FIGHT AGAINST INFECTIOUS DISEASES AND BIOTERRORISM, 2001, : 101 - 112
  • [30] Tuberculosis in Australia: bacteriologically confi rmed cases and drug resistance, 2004 A Report of the Australian Mycobacterium Reference Laboratory Network
    Lumb, Richard
    Bastian, Ivan
    Crighton, Taryn
    Gilpin, Chris
    Haverkort, Frank
    Sievers, Aina
    COMMUNICABLE DISEASES INTELLIGENCE, 2006, 30 (01) : 102 - 108